SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. DNLI today announced the pricing of its underwritten public offering of 10,377,359 common shares at a public price of $26.50 per share. All shares are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,556,603 common shares. Before deducting underwriting rebates and commissions and estimated issuing costs, Denali Therapeutics expects total gross proceeds of approximately $275 million, subject to the non-exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about October 24, 2022, subject to satisfaction of customary closing conditions.
Goldman Sachs & Co. LLC, JP Morgan Securities LLC and Jefferies LLC are acting as joint book-running managers for the offering. Berenberg Capital Markets LLC, Cantor Fitzgerald & Co. and HC Wainwright & Co., LLC are acting as co-managers for the offering.
Denali Therapeutics has filed a registration statement on Form S-3, effective automatically upon filing with the SEC on February 28, 2022, and filed a preliminary prospectus supplement and an accompanying prospectus relating to the offering on October 18, 2022. A definitive prospectus supplement and an accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed free of charge through the SEC’s website at www.sec.gov.
If available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from:
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, Telephone: 1-866-471-2526, Fax: 212-902-9316, Email: prospectus-ny@ny .e-mail. gs.com; JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,…
